Antibody against clotting factor prevents thrombosis without increasing bleeding risk
Posted March 17, 2014 by lorrainegenscript
A recent publication in Science Translational Medicine describes the use of a humanized monoclonal antibody against activated FXIIa, identified using phage display, to prevent the formation of blood clots without increasing the risk of bleeding.
Feature News
FXIIa, identified using phage display, to prevent the formation of blood clots without increasing the risk of bleeding. Preventing
thrombus formation while using a bypass system often leads to unwanted bleeding, sometimes in the brain, making this breakthrough
treatment an attractive alternative to heparin.
GenScript offers Custom mAb production services to develop your specific antibody and Antibody Library and Phage Display services
which can build a library with up to 1010 individual clones.
-- END ---
| Contact Email | [email protected] |
| Issued By | lorraine xu |
| Website | A recent publication in Science Translational Medicine describes the use of a humanized monoclonal antibody against activated FXIIa, identified using phage display, to prevent the formation of blood clots without increasing the risk of bleeding. Prevent |
| Country | China |
| Categories | Health |
| Tags | antibody , genscript |
| Last Updated | March 17, 2014 |